YHB Investment Advisors Inc. Reduces Stock Position in Bristol-Myers Squibb (NYSE:BMY)

YHB Investment Advisors Inc. lowered its stake in Bristol-Myers Squibb (NYSE:BMY) by 1.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,168 shares of the biopharmaceutical company’s stock after selling 518 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $1,343,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Riversedge Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 3.2% during the 3rd quarter. Riversedge Advisors LLC now owns 5,691 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 178 shares during the last quarter. Vicus Capital increased its stake in shares of Bristol-Myers Squibb by 3.9% during the 3rd quarter. Vicus Capital now owns 4,824 shares of the biopharmaceutical company’s stock valued at $280,000 after acquiring an additional 179 shares during the last quarter. Front Row Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 17.5% during the 4th quarter. Front Row Advisors LLC now owns 1,222 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 182 shares during the last quarter. Cassia Capital Partners LLC increased its stake in shares of Bristol-Myers Squibb by 2.3% during the 3rd quarter. Cassia Capital Partners LLC now owns 7,931 shares of the biopharmaceutical company’s stock valued at $460,000 after acquiring an additional 182 shares during the last quarter. Finally, Lindbrook Capital LLC increased its stake in shares of Bristol-Myers Squibb by 2.3% during the 3rd quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company’s stock valued at $468,000 after acquiring an additional 182 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BMY. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Bank of America downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $68.00 to $60.00 in a research report on Wednesday, January 3rd. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, Wells Fargo & Company decreased their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $61.12.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock traded down $0.84 during midday trading on Friday, hitting $48.28. The company’s stock had a trading volume of 12,459,210 shares, compared to its average volume of 16,886,538. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The stock’s 50-day moving average price is $51.28 and its 200-day moving average price is $51.84. Bristol-Myers Squibb has a 12 month low of $47.58 and a 12 month high of $70.93. The company has a market capitalization of $97.85 billion, a PE ratio of 12.51, a price-to-earnings-growth ratio of 1.51 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. During the same period in the previous year, the business earned $1.82 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up .6% compared to the same quarter last year. Analysts anticipate that Bristol-Myers Squibb will post 6.49 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.97%. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.